Imrab 1 - 1905.25

Verify with FDA CVM →

23 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
23
Total Reports
2
Deaths Reported
870.0%
Death Rate

Active Ingredients

Imrab 1 - 1905.25

Administration Routes

SubcutaneousUnknown

Species Affected

Dog 18
Cat 5

Most Affected Breeds

Crossbred Canine/dog 3
Chihuahua 2
Poodle - Toy 2
Mixed (Cat) 2
Retriever - Golden 2
Domestic Shorthair 2
Retriever - Labrador 2
Brittany 1
Domestic Longhair 1
Weimaraner 1

Most Reported Reactions

Vomiting 10
Lethargy (see also Central nervous system depression in 'Neurological') 3
Diarrhoea 3
Inappetence 2
Decreased appetite 2
Vocalisation 2
Elevated temperature 2
Drooling 2
Not eating 2
Lethargy (see also Central nervous system depression in Neurological) 2
Elevated serum alkaline phosphatase (ALP) 2
Monocytosis 2

Outcome Breakdown

Outcome Unknown
8 (34.8%)
Recovered/Normal
8 (34.8%)
Ongoing
5 (21.7%)
Euthanized
1 (4.3%)
Died
1 (4.3%)

Data Summary

Metric Value
Total adverse event reports 23
Reports involving death 2
Case-fatality rate (reported events) 870.0%
Distinct species in reports 2
Distinct breeds in reports 15
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Imrab 1 - 1905.25 Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 23 adverse event reports referencing Imrab 1 - 1905.25, including 2 reports in which the animal died — a 870.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Imrab 1 - 1905.25. Reported administration routes include Subcutaneous, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Imrab 1 - 1905.25 reports are Dog (18 reports), Cat (5 reports), with Dog accounting for the largest share. Within those species, Crossbred Canine/dog (3), Chihuahua (2), Poodle - Toy (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Imrab 1 - 1905.25 are Vomiting (10), Lethargy (see also Central nervous system depression in 'Neurological') (3), Diarrhoea (3), Inappetence (2). Of the 23 reports with a coded outcome, Outcome Unknown is the leading category at 34.8%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Imrab 1 - 1905.25.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial